8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 5, 2026·SEC
Zentalis Pharmaceuticals, Inc.(ZNTL)Earnings, Financials & Key Ratios
ZNTL•NASDAQ
$4.72
Price updated Jul 6, 2026
AboutZentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.Show more
- Revenue$0-100.0%
- EBITDA-$152M+19.9%
- Net Income-$137M+17.4%
- EPS (Diluted)-1.91+18.0%
- ROE-49.53%-15.7%
ZNTL Price & Volume
Zentalis Pharmaceuticals, Inc. (ZNTL) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Zentalis Liquidity Position
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical hold and liquidity
Key Thesis Takeaways
- Zentalis Pharmaceuticals faces a precarious outlook characterized by a lack of recurring revenue and a rapid depletion of capital reserves to fund its high-intensity R&D pipeline.
- The company's reliance on non-recurring milestone payments has resulted in extreme top-line volatility, while accumulated losses of $1.2 billion continue to erode shareholder equity.
- Investors should monitor the company's ability to secure additional financing, as the current cash position of $31.9 million appears insufficient to sustain long-term clinical development without significant dilution.
Verdict Logic
the company's cash reserves have dwindled to $31.9 million as of 2026Q1, creating a critical liquidity risk that likely necessitates further dilutive financing.
ZNTL Growth Metrics
Zentalis Pharmaceuticals, Inc. (ZNTL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM44.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM44.9%
Return on Capital
10 Years-58.96%
5 Years-51.75%
3 Years-51%
Last Year-48.51%
ZNTL Recent Earnings
Zentalis Pharmaceuticals, Inc. (ZNTL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.50-2.0%
$0.49
Rev
—
—
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$0.49-19.5%
$0.41
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.37+24.5%
$0.49
Rev
—
—
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.37+33.9%
$0.56
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.50vs $0.49-2.0% | — |
| Q2 2026 | Mar 26, 2026 | $0.49vs $0.41-19.5% | — |
| Q4 2025 | Nov 10, 2025 | $0.37vs $0.49+24.5% | — |
| Q3 2025 | Aug 6, 2025 | $0.37vs $0.56+33.9% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Zentalis Pharmaceuticals, Inc. (ZNTL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.72 | $336M | -2.47 | -100% | — | -49.53% | — | |
| $189.99 | $40.39B | -31.93 | — | — | -83.22% | — | |
| $114.76 | $9.37B | -31.10 | -16.72% | -612.17% | -25.02% | — | |
| $15.49 | $1.99B | 7.48 | 20.38% | 99.97% | 64.48% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — |
Compare ZNTL vs Peers
Zentalis Pharmaceuticals, Inc. (ZNTL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ZNTL SEC Filings & Documents
Zentalis Pharmaceuticals, Inc. (ZNTL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ZNTL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ZNTL Frequently Asked Questions
Zentalis Pharmaceuticals, Inc. (ZNTL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Zentalis Pharmaceuticals, Inc. growing?
Zentalis Pharmaceuticals, Inc. (ZNTL) saw revenue decline by 100.0% over the past year.
Is ZNTL profitable?
Zentalis Pharmaceuticals, Inc. (ZNTL) reported a net loss of $124.1M for fiscal year 2025.
Dividend & Returns
What is ZNTL's return on equity?
Zentalis Pharmaceuticals, Inc. (ZNTL) has a return on equity (ROE) of -49.5%. Negative ROE indicates the company is unprofitable.
What is Zentalis Pharmaceuticals, Inc.'s free cash flow?
Zentalis Pharmaceuticals, Inc. (ZNTL) had negative free cash flow of $125.6M in fiscal year 2025, likely due to heavy capital investments.